Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. AVROBIO, Inc.
  6. News
  7. Summary
    AVRO   US05455M1009

AVROBIO, INC.

(AVRO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Mizuho Adjusts AVROBIO's Price Target to $6 from $28, Keeps Buy Rating

01/06/2022 | 09:50am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about AVROBIO, INC.
05/18AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society o..
BU
05/18AVROBIO, Inc. Announces Preclinical Data Demonstrating the Efficacy and Safety of AVR-R..
CI
05/17Needham Adjusts AVROBIO's Price Target to $6 from $8, Keeps Buy Rating
MT
05/17AVROBIO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05/17AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene The..
BU
05/17Avrobio Reports Positive Data from Phase 1/2 Clinical Trial of Investigational Gene The..
CI
05/16AVROBIO to Present at the H.C. Wainwright Global Investment Conference
BU
05/11Barclays Adjusts AVROBIO's Price Target to $4 from $6, Keeps Overweight Rating
MT
05/10AVROBIO, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/10AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update
BU
More news
Analyst Recommendations on AVROBIO, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -108 M - -
Net cash 2022 82,4 M - -
P/E ratio 2022 -0,33x
Yield 2022 -
Capitalization 32,1 M 32,1 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 122
Free-Float 97,4%
Chart AVROBIO, INC.
Duration : Period :
AVROBIO, Inc. Technical Analysis Chart | AVRO | US05455M1009 | MarketScreener
Technical analysis trends AVROBIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 0,75 $
Average target price 4,57 $
Spread / Average Target 509%
EPS Revisions
Managers and Directors
Geoff MacKay President, Chief Executive Officer & Director
Erik John Ostrowski Chief Financial Officer & Treasurer
Bruce Lee Booth Chairman
Christopher Mason Chief Scientific Officer
Kim Raineri Chief Manufacturing & Technical Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
AVROBIO, INC.-80.50%32
GILEAD SCIENCES, INC.-12.93%79 298
REGENERON PHARMACEUTICALS, INC.4.38%71 026
VERTEX PHARMACEUTICALS14.91%64 540
WUXI APPTEC CO., LTD.-18.77%41 409
BIONTECH SE-39.08%38 169